SRZN: Ascending Triangle detected on 1 Apr 2026

SRZN is forming an ascending triangle with perfect structure (15.0/15) as price consolidates near resistance at $29.46, just 1.1% below the 52-week high of $29.59. The pattern displays clean higher lows, tested resistance, and strong volume confirmation (12.0/12) with current volume at 182,293 shares (1.9x the 20-day average). Breakout quality scores 13.0/13, indicating institutional accumulation ahead of the planned H2 2026 IND submission for SZN-8141. RSI at 61.5 shows measured momentum without overbought extremes. The overall pattern quality scores 83, with 63.3% win probability.

On March 23, 2026, Surrozen reported full-year 2025 results with planned IND submission for SZN-8141 in H2 2026 and a $5.0M milestone payment from Boehringer Ingelheim for SZN-413. Major shareholder TCG Crossover GP II acquired 106,658 shares on March 24, 2026 at an average price of $24.69 per share—demonstrating institutional conviction right as this pattern formed. Guggenheim reiterated a Buy rating with $42.00 price target following fiscal 2025 earnings, and HC Wainwright raised its target to $36.00 from $32.00. An IND clearance for SZN-8141 will trigger $98.4M from the company's recent $175M financing. Cash position of $89.2M provides 2-3 year runway to key clinical milestones.

A clean breakout above $29.46 resistance would complete the ascending triangle structure. The measured move target of $30.92 represents just 6.1% upside, suggesting early institutional positioning ahead of near-term catalysts. The pattern indicates volume confirmation likely to increase above 200K shares as traders recognize the breakout. If SZN-8141 progresses toward IND filing without material setbacks, the $30.92 level becomes a short-term stopping point before potential continuation toward analyst price targets of $36-$42. Invalidation occurs below $23.77 (key support), which would negate the bullish setup and suggest distribution phase. With 63.3% win probability, this is a solid intermediate-term breakout structure.

SRZN reported Q1 2026 EPS of ($7.59), missing consensus by ($6.30), with only $0.53M revenue versus $0.66M expected. Clinical-stage losses total $86.9M annually; binary risks mean IND delays or trial failures could trigger 50-70% stock declines. Recent rally suggests consolidation likely in $20-$22 range before next leg higher. Weiss Ratings maintains a sell rating while analysts are generally bullish—creating analyst consensus risk if clinical data disappoints. The stock appears overvalued relative to Fair Value estimates per InvestingPro. Healthcare sector trades bearish (-0.09 regime score) and overall market is bearish (-0.46), creating headwinds. Low beta (0.35) offers some downside cushion, but small-cap liquidity constraints could amplify volatility if institutional holders trim positions post-IND filing announcement.